Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Total Valuation
Haemonetics has a market cap or net worth of $2.66B. The enterprise value is $4.50B.
Market Cap$2.66B
Enterprise Value$4.50B
Share Statistics
Haemonetics has 48,177,258 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,177,258
Owned by Insiders1.34%
Owned by Institutions30.85%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 8.06%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)8.06%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee372.11K
Profits Per Employee45.85K
Employee Count3,657
Asset Turnover0.56
Inventory Turnover1.68
Valuation Ratios
The current PE Ratio of Haemonetics is 16.8. Haemonetics’s PEG ratio is ―.
PE Ratio16.8
PS Ratio―
PB Ratio―
Price to Fair Value3.87
Price to FCF―
Price to Operating Cash Flow11.44
PEG Ratio―
Income Statement
In the last 12 months, Haemonetics had revenue of 1.36B and earned 167.68M in profits. Earnings per share was 3.31.
Revenue1.36B
Gross Profit748.96M
Operating Income221.82M
Pretax Income212.07M
Net Income167.68M
EBITDA337.40M
Earnings Per Share (EPS)3.31
Cash Flow
In the last 12 months, operating cash flow was 226.54M and capital expenditures -37.38M, giving a free cash flow of 189.16M billion.
Operating Cash Flow226.54M
Free Cash Flow189.16M
Free Cash Flow per Share3.93
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change-27.91%
50-Day Moving Average68.15
200-Day Moving Average70.14
Relative Strength Index (RSI)32.27
Average Volume (3m)1.05M
Important Dates
Haemonetics upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
Haemonetics as a current ratio of 1.62, with Debt / Equity ratio of 138.82%
Current Ratio1.62
Quick Ratio0.99
Debt to Market Cap0.39
Net Debt to EBITDA2.72
Interest Coverage Ratio-22.76
Taxes
In the past 12 months, Haemonetics has paid 44.39M in taxes.
Income Tax44.39M
Effective Tax Rate0.21
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 12.15, with an EV/FCF ratio of 28.77.
EV to Sales3.01
EV to EBITDA12.15
EV to Free Cash Flow28.77
EV to Operating Cash Flow22.55
Balance Sheet
Haemonetics has $292.90M in cash and marketable securities with $1.22B in debt, giving a net cash position of $931.88M billion.
Cash & Marketable Securities$292.90M
Total Debt$1.22B
Net Cash$931.88M
Net Cash Per Share$19.34
Tangible Book Value Per Share-$4.75
Margins
Gross margin is 56.05%, with operating margin of 16.30%, and net profit margin of 12.32%.
Gross Margin56.05%
Operating Margin16.30%
Pretax Margin15.58%
Net Profit Margin12.32%
EBITDA Margin24.79%
EBIT Margin16.30%
Analyst Forecast
The average price target for Haemonetics is $73.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$73.00
Price Target Upside34.34% Upside
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast0.91%
EPS Growth Forecast45.81%